RxDoctor Payments Data

Shervin Eshraghi, MD

Neurology · Valencia, CANPI 1538191507

Payments from drug & device makers

$51,856in general payments, 2019–2025

Across 804 payments — averaging $64.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$8K
  • Supernus Pharmaceuticals, Inc.$7K
  • MDD US Operations, LLC$6K
  • Lundbeck LLC$5K
  • SK Life Science, Inc.$4K
  • Novartis$4K
  • plus $18K from 51 others

What the payments were for

  • Consulting fees$9,58818%
  • Speaking & faculty fees$13,32526%
  • Travel & lodging$3,5827%
  • Food & beverage$22,03642%
  • Education$5921%
  • Gifts$2,7335%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi68$7,817
Supernus Pharmaceuticals, Inc.81$7,118
MDD US Operations, LLC91$6,207
Lundbeck LLC14$4,549
SK Life Science, Inc.23$4,340
Novartis34$3,933
Teva Pharmaceuticals USA, Inc.82$1,854
Livanova USA, Inc.8$1,516
Sarepta Therapeutics, Inc.1$1,500
AstraZeneca(2 entities)20$1,312
AbbVie(2 entities)59$1,291
Biogen24$1,115
Amgen(2 entities)17$988
EMD Serono, Inc.25$696
Neurocrine Biosciences, Inc.11$631
Alnylam Pharmaceuticals Inc.11$527
Eisai Inc.14$524
Biohaven Pharmaceuticals, Inc.31$506
Avanir Pharmaceuticals, Inc.36$433
Argenx US, Inc.4$354
Sunovion Pharmaceuticals Inc.12$348
Abbott3$346
Lilly USA, LLC13$328
Otsuka America Pharmaceutical, Inc.7$254
Sumitomo Pharma America, Inc.4$250
Genentech USA, Inc.7$245
Grifols USA, LLC7$240
Johnson & Johnson7$220
UCB, Inc.10$207
Jazz Pharmaceuticals Inc.9$200
Acadia Pharmaceuticals Inc2$169
Tanabe Pharma America, Inc.8$164
Amneal Pharmaceuticals LLC8$149
Biohaven Pharmaceutical Holding Company Ltd.1$127
Penumbra, Inc.2$126
Genentech, Inc.2$125
Itamar Medical Inc1$115
Arbor Pharmaceuticals, Inc.5$111
Upsher-smith Laboratories LLC7$102
Pfizer3$94
Greenwich Biosciences, Inc.4$94
Neurelis, Inc.3$79
Harmony Biosciences LLC4$78
Adamas Pharmaceuticals, Inc.2$69
Bausch Health US, LLC3$58
GE HealthCare3$53
Scilex Pharmaceuticals Inc.1$53
Fujirebio Diagnostics, Incorporated1$52
Assertio Therapeutics, Inc.2$37
Sanofi-aventis U.S. LLC2$33
Acorda Therapeutics, Inc1$25
Bristol Myers Squibb1$23
Aquestive Therapeutics, Inc.1$19
Vanda Pharmaceuticals Inc.1$18
Catalyst Pharmaceuticals, Inc.1$12
Boston Scientific1$12
Kaleo, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$51,856 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$57,150
Medicare patients
190
Services billed
1,489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4623$204,694
BriviactBrivaracetam15$20,555
Rasagiline Mesylate25$9,871
Aimovig AutoinjectorErenumab-Aooe11$8,218
Emgality PenGalcanezumab-Gnlm12$8,039
Memantine Hcl76$1,617
Propranolol Hcl ErPropranolol Hcl38$1,518
Donepezil Hcl134$1,247
Carbidopa-LevodopaCarbidopa/Levodopa53$1,200
Galantamine ErGalantamine Hbr13$1,085
Pregabalin50$820
Levetiracetam14$515
Eletriptan HbrEletriptan Hydrobromide20$489
Primidone35$394
Divalproex Sodium ErDivalproex Sodium21$374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$240$204,69423 claims
UCB, Inc.Briviact$207$20,55515 claims
Upsher-smith Laboratories LLCTopiramate$102$5213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,996 neurology providers in California.

Other neurology in Valencia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →